These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Characteristics of injectable contraceptive users in a low-income population in Texas. Sangi-Haghpeykar H; Poindexter AN; Moseley DC; Bateman L; Reid ED Fam Plann Perspect; 1995; 27(5):208-11, 225. PubMed ID: 9104608 [TBL] [Abstract][Full Text] [Related]
4. Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658 [TBL] [Abstract][Full Text] [Related]
5. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues? Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125 [TBL] [Abstract][Full Text] [Related]
6. Program- and method-related determinants of first DMPA use duration in rural Bangladesh. Riley AP; Stewart MK; Chakraborty J Stud Fam Plann; 1994; 25(5):255-67. PubMed ID: 7871551 [TBL] [Abstract][Full Text] [Related]
7. Statement on injectable contraception. International Planned Parenthood Federation IPPF IPPF Med Bull; 1982 Dec; 16(6):3-4. PubMed ID: 12338511 [TBL] [Abstract][Full Text] [Related]
8. A comparison of levonorgestrel implants with depo-medroxyprogesterone acetate injections for contraception. London RS J SOGC; 1993 Oct; 15(8):925-8, 32. PubMed ID: 12318530 [TBL] [Abstract][Full Text] [Related]
9. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Polaneczky M; Guarnaccia M; Alon J; Wiley J Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283 [TBL] [Abstract][Full Text] [Related]
11. Injectable contraception: the USA perspective. Kaunitz AM IPPF Med Bull; 1992 Dec; 26(6):1-3. PubMed ID: 12346920 [TBL] [Abstract][Full Text] [Related]
12. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. Nelson AL J Reprod Med; 1996 May; 41(5 Suppl):391-400. PubMed ID: 8725701 [TBL] [Abstract][Full Text] [Related]
13. [Acceptability of medroxyprogesterone acetate in rural areas of Mexico]. Velasco Murillo V; Cervantes Bustamante A; Correu Azcona S; García López E Ginecol Obstet Mex; 1981 Mar; 49(293):153-61. PubMed ID: 6459270 [TBL] [Abstract][Full Text] [Related]
14. Use of depo-provera in teens. Khoiny FE J Pediatr Health Care; 1996; 10(5):195-201. PubMed ID: 8920351 [TBL] [Abstract][Full Text] [Related]
15. Facts about injectable contraceptives: memorandum from a WHO meeting. Bull World Health Organ; 1982; 60(2):199-210. PubMed ID: 6213318 [TBL] [Abstract][Full Text] [Related]
16. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. Kaunitz AM J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705 [TBL] [Abstract][Full Text] [Related]
17. Knowledge, attitude and practice of family planning among senior high school students in north Gonder. Fantahun M; Chala F; Loha M Ethiop Med J; 1995 Jan; 33(1):21-9. PubMed ID: 7895743 [TBL] [Abstract][Full Text] [Related]
18. Acceptability study of the two versus three monthly injectable contraceptives. Aly FA; El-genedi MM; Toppozada HK; El-abd M; Loutfi I Dirasat Sukkaniyah; 1984; 11(69):27-39. PubMed ID: 12179796 [TBL] [Abstract][Full Text] [Related]
19. Use of depot medroxyprogesterone acetate contraception in adolescents. Davis AJ J Reprod Med; 1996 May; 41(5 Suppl):407-13. PubMed ID: 8725703 [TBL] [Abstract][Full Text] [Related]